🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Clear Cell Renal Cell Carcinoma

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma NCT07469683Phase 21 site📍 Seoul Yonsei University · Tests: SLC-3010 + Axitinib, Axitinib Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor NCT03093688Phase 1, Phase 21 site📍 Shanghai Shanghai Public Health Clinical Center · Tests: Infusion of iNKT cells and CD8+T cells A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer NCT07128680Phase 12 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formul… Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT07011719Phase 3183 sites📍 Gilbert📍 Goodyear📍 Phoenix Arcus Biosciences, Inc. · Tests: Casdatifan, Cabozantinib, Placebo Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024Phase 18 sites📍 Boston📍 Ann Arbor📍 St Louis Deciphera Pharmaceuticals, LLC · Tests: DCC-2812 IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) NCT05665361Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sasanlimab, Palbocicilib Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer NCT07227415Phase 1, Phase 2183 sites📍 Phoenix📍 Scottsdale📍 Fayetteville Pfizer · Tests: PF-08634404, Ipilimumab, Axitinib, Casdatifan Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC NCT06863311Phase 25 sites📍 La Jolla📍 Indianapolis📍 St Louis Karie Runcie · Tests: XL092, Nivolumab PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk NCT07175480Phase 21 site📍 Nanjing Jinling Hospital, China · Tests: Intermittent PD-1/PD-L1 ICI + VEGFR-TKI Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042Phase 1, Phase 26 sites📍 Scottsdale📍 Denver📍 New Haven Simcha IL-18, Inc. · Tests: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab Sitagliptin With Pembro in RCC and Melanoma NCT07634380Phase 11 site📍 Iowa City Fernando Maciel Barbosa · Tests: Sitagliptin, Pembrolizumab Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site📍 Adelaide SAPU NANO (US) LLC · Tests: Sapu003, Exemestane 25 MG Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma NCT07611825Phase 22 sites📍 Nanjing📍 Nanjing Jinling Hospital, China · Tests: Toripalimab, Ipilimumab Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC NCT07172386Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Toripalimab and axitinib To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer NCT07647744Phase 11 site📍 Shanghai Hrain Biotechnology Co., Ltd. · Tests: Anti-Human CD70 T-Cell Injection A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) NCT07227402Phase 3127 sites📍 Anchorage📍 Fullerton📍 Los Angeles Merck Sharp & Dohme LLC · Tests: Belzutifan, Zanzalintinib, Cabozantinib A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC NCT06332755Phase 11 site📍 Fairfax LG Chem · Tests: Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NCT06805825Phase 15 sites📍 Ann Arbor📍 Cleveland📍 Portland Novelty Nobility, Inc. · Tests: NN3201 Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma NCT07564232Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Cyclophosphamide, Fludarabine, LNK001 Imaging of Solid Tumors Using 18F-TRX NCT06942104Phase 11 site📍 San Francisco Rahul Aggarwal · Tests: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766Phase 1, Phase 242 sites📍 Duarte📍 Glendale📍 Los Angeles Inhibrx Biosciences, Inc · Tests: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplati…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy